A 2026 mechanistic study involving 28 healthy adults found that a single 25 mg psilocybin session changed acute brain entropy, psychological insight, well-being, cognitive flexibility, and some MRI-derived white-matter signals for up to 1 month. Research Highlights Acute brain entropy rose clearly: 25 mg psilocybin increased Lempel-Ziv complexity (LZc; a measure of signal irregularity) at …
A 2026 study involving 32 adult mangrove rivulus fish pairs found that 3,000 µg/L waterborne psilocybin reduced movement and aggressive swimming bursts, but the result belongs in animal behavioral pharmacology, not in human aggression treatment claims.1 Research Highlights Fish movement decreased: psilocybin produced a treatment-by-time interaction for time spent moving (p = 0.006), with a …
A 2026 eLife computational study modeled classical psychedelics by increasing a network state variable from alpha = 0 to alpha = 1, shifting perception from bottom-up sensory inference toward top-down generative replay. The result is a useful but still unproven oneirogen model: hallucinations look less like random noise and more like wake-time replay of a …
Psychedelic-assisted therapy has been one of the most-covered mental-health stories of the past decade. A 2026 quantitative analysis by Evers and colleagues maps how media enthusiasm grew, peaked, and partially pulled back across major U.S. outlets — and how the coverage related to the actual evidence base for depression and PTSD.1 Research Highlights Psychedelic clinical …
Media coverage of psychedelics outpaces the trial evidence. MDMA-PTSD signals are large; psilocybin-depression effects shrink against active comparators.
Recent research has provided compelling evidence on the therapeutic potential of psilocybin, a naturally occurring psychedelic, in treating depression. A systematic review and dose-response meta-analysis shed light on the optimal dosage of psilocybin for depression, revealing variations in effectiveness based on patient subgroups and associated risks. Highlights: Psilocybin showed significant antidepressant effects, with optimal dosages …
Psychedelic compounds, long associated with the fringes of medicine and spirituality, are now at the forefront of a radical shift in neurology and psychiatry. Decades of clinical trials have begun to unravel the therapeutic potentials of these substances, revealing promising outcomes in the treatment of various psychiatric disorders. However, a notable gap in this burgeoning …